Raising approximately AUD $35 million, exceeding the minimum required to complete the acquisition of Adheris Health.
Adheris’ strong sales pipeline of health programs relating to pharmaceuticals and vaccines built this quarter provides confidence for FY21 sales growth.
Major shareholder HMS and a number MedAdvisor directors have participated in the round.
The market might want to see a first quarter of Adheris revenue under MDR before the share price lifts.
MDR Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
